Merck projects $200 million in tariff costs, boosts U.S. manufacturing plans, and continues M&A efforts amid external pressures and shifting market dynamics.

Merck & Co., Inc. (MRK) is currently at $82.84, up $3.00 or 3.76% --Would be highest close since April 3, 2025, when it closed at $86.39 --On pace for largest percent increase since March 27, 2024, ...

BMO Capital analyst Evan Seigerman lowered the firm’s price target on Merck (MRK) to $82 from $89 and keeps a Market Perform rating on the ...

LOS ANGELES, April 13, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Merck & Co., Inc. ("Merck" or " ...

It is an injected therapy called ivonescimab that has shown favorable results versus Merck’s $29.5-billion ... Summit’s head of business and strategy. Instead, she wanted a close partnership ...

as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that Merck lacked ...

LOS ANGELES, April 10, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Merck & Co., Inc. ("Merck" or the "Company") (NYSE: MRK) investors of a class action representing investors that bought ...

If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us. Charles Linehan, ...

Inflation throttled back in March, largely on lower gasoline prices — but tariffs threaten to reverse that downward trend in coming months while trouble also lurks in certain categories like ...